temozolomide has been researched along with Seizures in 23 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone." | 9.34 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 9.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 9.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)." | 8.12 | Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022) |
| "We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy." | 7.83 | Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 7.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Fresh suspected glioblastoma tissue was collected during surgery, and patients with pathology-confirmed GBM enrolled before starting concurrent Radiation Therapy and Temozolomide (RT/TMZ) with Intent to Treat (ITT) after recovery from RT/TMZ." | 5.51 | Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. ( Abedi, M; Aiken, RD; Bota, DA; Bota, PG; Carrillo, JA; Dillman, RO; Duma, CM; Hsieh, C; Hsu, FPK; Keirstead, HS; Kesari, S; Kong, XT; LaRocca, RV; Nistor, GI; Piccioni, DE; Taylor, TH, 2022) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 5.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "All patients had seizure disorders that were treated with anticonvulsants." | 5.37 | Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011) |
| " In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone." | 5.34 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 5.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 5.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)." | 4.12 | Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022) |
| "We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy." | 3.83 | Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 3.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Glioblastoma is almost always incurable and most older patients survive less than 6 months." | 2.53 | How I treat glioblastoma in older patients. ( Mohile, NA, 2016) |
| "We identified the preoperative seizure frequency threshold by plotting a receiver operating characteristic curve." | 1.56 | Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas. ( Chen, Q; Deng, G; Gao, L; Jiang, H; Liu, B; Tan, Y; Wang, J; Yang, K; Yuan, F, 2020) |
| "Controlling seizures is essential during GBM treatment because they are often present and closely associated with the quality of life of GBM patients." | 1.51 | Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. ( Chang, MJ; Min, KL; Ryu, JY, 2019) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 1.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Thromboembolic events, seizures, neurologic symptoms and adverse effects from corticosteroids and chemotherapies are frequent clinical complications seen in Glioblastoma (GB) patients." | 1.42 | Risk factors for glioblastoma therapy associated complications. ( Brenke, C; Capper, D; Ening, G; Osterheld, F; Schmieder, K, 2015) |
| "Clinical presentation of gliomatosis cerebri is variable and depends on the degree, extent, and location of cortical involvement." | 1.39 | Bilateral ptosis as initial presentation of gliomatosis cerebri: case report. ( Braca, J; Kovanda, T; Prabhu, V, 2013) |
| "All patients had seizure disorders that were treated with anticonvulsants." | 1.37 | Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011) |
| "Temozolomide is an effective treatment for seizure control in patients with brain tumors." | 1.37 | Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients. ( Hu, A; Kesari, S; Kim, RY; Lee, JW; Nguyen, A; Xu, Z, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 15 (65.22) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Cucchiara, F | 1 |
| Luci, G | 1 |
| Giannini, N | 1 |
| Giorgi, FS | 1 |
| Orlandi, P | 1 |
| Banchi, M | 1 |
| Di Paolo, A | 1 |
| Pasqualetti, F | 1 |
| Danesi, R | 1 |
| Bocci, G | 1 |
| Bota, DA | 2 |
| Taylor, TH | 2 |
| Piccioni, DE | 2 |
| Duma, CM | 2 |
| LaRocca, RV | 2 |
| Kesari, S | 3 |
| Carrillo, JA | 2 |
| Abedi, M | 2 |
| Aiken, RD | 2 |
| Hsu, FPK | 2 |
| Kong, XT | 2 |
| Hsieh, C | 2 |
| Bota, PG | 2 |
| Nistor, GI | 2 |
| Keirstead, HS | 2 |
| Dillman, RO | 2 |
| Ryu, JY | 1 |
| Min, KL | 1 |
| Chang, MJ | 1 |
| Jiang, H | 1 |
| Liu, B | 1 |
| Deng, G | 1 |
| Yuan, F | 1 |
| Tan, Y | 1 |
| Yang, K | 1 |
| Gao, L | 1 |
| Wang, J | 2 |
| Chen, Q | 1 |
| Climans, SA | 1 |
| Brandes, AA | 1 |
| Cairncross, JG | 1 |
| Ding, K | 1 |
| Fay, M | 1 |
| Laperriere, N | 1 |
| Menten, J | 1 |
| Nishikawa, R | 1 |
| O'Callaghan, CJ | 1 |
| Perry, JR | 1 |
| Phillips, C | 1 |
| Roa, W | 1 |
| Wick, W | 1 |
| Winch, C | 1 |
| Mason, WP | 1 |
| Jiao, Y | 1 |
| Wang, M | 1 |
| Liu, X | 1 |
| Wang, Z | 1 |
| Luo, W | 1 |
| Yu, Y | 1 |
| Sun, H | 1 |
| Kovanda, T | 1 |
| Braca, J | 1 |
| Prabhu, V | 1 |
| Barker, CA | 1 |
| Bishop, AJ | 1 |
| Chang, M | 1 |
| Beal, K | 1 |
| Chan, TA | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 1 |
| Zwinkels, H | 1 |
| Walchenbach, R | 1 |
| Taphoorn, MJ | 3 |
| Vecht, CJ | 1 |
| Koekkoek, JA | 2 |
| Dirven, L | 2 |
| Heimans, JJ | 2 |
| Postma, TJ | 2 |
| Vos, MJ | 2 |
| Reijneveld, JC | 2 |
| Rees, J | 1 |
| Ening, G | 1 |
| Osterheld, F | 1 |
| Capper, D | 1 |
| Schmieder, K | 1 |
| Brenke, C | 1 |
| Roelcke, U | 1 |
| Wyss, MT | 1 |
| Nowosielski, M | 1 |
| Rudà, R | 2 |
| Roth, P | 1 |
| Hofer, S | 1 |
| Galldiks, N | 1 |
| Crippa, F | 1 |
| Weller, M | 1 |
| Soffietti, R | 2 |
| Mohile, NA | 1 |
| Toler, J | 1 |
| Deputy, S | 1 |
| Zakris, E | 1 |
| Bégué, RE | 1 |
| Pellerino, A | 1 |
| Sherman, JH | 1 |
| Moldovan, K | 1 |
| Yeoh, HK | 1 |
| Starke, RM | 1 |
| Pouratian, N | 1 |
| Shaffrey, ME | 1 |
| Schiff, D | 1 |
| Hu, A | 1 |
| Xu, Z | 1 |
| Kim, RY | 1 |
| Nguyen, A | 1 |
| Lee, JW | 1 |
| Davis, ME | 1 |
| Stoiber, AM | 1 |
| Brada, M | 1 |
| Viviers, L | 1 |
| Abson, C | 1 |
| Hines, F | 1 |
| Britton, J | 1 |
| Ashley, S | 1 |
| Sardell, S | 1 |
| Traish, D | 1 |
| Gonsalves, A | 1 |
| Wilkins, P | 1 |
| Westbury, C | 1 |
| Pace, A | 1 |
| Vidiri, A | 1 |
| Galiè, E | 1 |
| Carosi, M | 1 |
| Telera, S | 1 |
| Cianciulli, AM | 1 |
| Canalini, P | 1 |
| Giannarelli, D | 1 |
| Jandolo, B | 1 |
| Carapella, CM | 1 |
| Menniti, A | 1 |
| Moschettoni, L | 1 |
| Liccardo, G | 1 |
| Lunardi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients[NCT00482677] | Phase 3 | 562 participants (Actual) | Interventional | 2007-11-14 | Completed | ||
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 13.47 |
| Radiation | 7.69 |
Time from date of randomization to the date of death of any causes, or censored at last known alive date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 9.33 |
| Radiation | 7.62 |
Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 5.29 |
| Radiation | 3.94 |
2 reviews available for temozolomide and Seizures
| Article | Year |
|---|---|
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumo | 2016 |
Glioblastoma multiforme: enhancing survival and quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplas | 2011 |
4 trials available for temozolomide and Seizures
| Article | Year |
|---|---|
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up Studi | 2020 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
17 other studies available for temozolomide and Seizures
| Article | Year |
|---|---|
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2022 |
Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2019 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Apraxias; Brain Neoplasms; Chemoradiotherapy, Adjuvan | 2021 |
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Blepharoptosis; Brain Neoplasms; Chemoradiothera | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Da | 2015 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysf | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Seizure control: a secondary benefit of chemotherapeutic temozolomide in brain cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Electroencephal | 2011 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Gliobl | 2005 |